Article in Annals of the American Thoracic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOYD, JAMES E · 2010 to 2020
$21.6M
Targeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M
Project 4: Defining the Molecular Natural History of Early and Progressive Pulmonary FibrosisP01HL172729 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Timothy S. Blackwell · 2024 to 2026
$11.2M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium DiseaseR01ES033678 · NIEHS · NATIONAL JEWISH HEALTH · PI LISA A MAIER, Ivana V Yang · 2022 to 2026
$3.1M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Epigenetic Regulation of Immune Pathways in SarcoidosisR01HL140357 · NHLBI · NATIONAL JEWISH HEALTH · PI MAIER, LISA A, YANG, IVANA V · 2018 to 2021
$2.8M
Defining the molecular and radiologic phenotype of progressive RA-ILDR01HL168126 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Joyce Sujin Lee · 2023 to 2026
$2.4M
Targeting dysfunctional epithelial repair in pulmonary fibrosisR01HL175555 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Timothy S. Blackwell · 2024 to 2026
$1.9M
Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseK23HL138131 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LEE, JOYCE SUJIN · 2017 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.